Annual cost of MS therapies by select countries 2013-2014

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

This statistic describes an annual cost comparison of multiple sclerosis (MS) drugs in the United States and other select countries, as of 2013 (or 2014). At this time, Avonex cost on average 30,273 U.S. dollars per year for the U.S. Department of Veterans Affairs and 18,641 U.S. dollars in Canada.

Multiple sclerosis drug annual cost in selected countries in 2013/2014 (in U.S. dollars)

Characteristic	U.S. Medicaid	U.S. Department of Veterans Affairs	Canada	Australia	United Kingdom
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

April 2015

More information

Region

Worldwide, United States

Survey time period

2013 and 2014

Supplementary notes

MS: multiple sclerosis
Further sources: Pharmaceutical Benefits Scheme (Australia), Ontario Ministry of Health and Long-Term Care (Canada), British National Formulary (UK).
* Interfereon-ß-1b is marketed as Betaseron (Bayer) and Extavia (Novartis).
** Natalizumab was withdrawn from the market in February 2005 to evaluate progressive multifocal leukoencephalopathy risk and was reintroduced in June 2006.
*** Price pending in Canada.

Open this statistic in...

Spanish

Citation formats